© 2012

Renal Cell Carcinoma

Translational Biology, Personalized Medicine, and Novel Therapeutic Targets

  • Robert A. Figlin
  • W. Kimryn Rathmell
  • Brian I. Rini

Table of contents

  1. Front Matter
    Pages i-xi
  2. Biology of Renal Cell Carcinoma

    1. Front Matter
      Pages 1-1
    2. Laura S. Schmidt, Ramaprasad Srinivasan, W. Marston Linehan
      Pages 3-25
    3. William G. Kaelin Jr.
      Pages 27-47
    4. Bin Tean Teh, Leslie J. Farber, Kyle Furge
      Pages 91-111
  3. Current and Future Molecular Targets for RCC

    1. Front Matter
      Pages 113-113
    2. Cristina Suarez, Brian I. Rini
      Pages 115-133
    3. James Brugarolas
      Pages 161-191
    4. Swathi Ramakrishnan, Roberto Pili
      Pages 193-211
    5. Hema Vankayala, Patricia LoRusso, Ulka Vaishampayan
      Pages 213-238
    6. Sumanta Kumar Pal, Karen Reckamp, Hua Yu, Robert A. Figlin, Robert A. Figlin, Robert A. Figlin
      Pages 239-252
    7. Hyung L. Kim, Edwin M. Posadas, Robert A. Figlin, Robert A. Figlin, Robert A. Figlin
      Pages 271-282
  4. Back Matter
    Pages 323-327

About this book


This volume examines every major topic area in the modern era of renal carcinoma biology and treatment.   The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease.  These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy.  

Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways.   This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations.


Carcinoma Renal Renal Cell prognostic therapeutic

Editors and affiliations

  • Robert A. Figlin
    • 1
  • W. Kimryn Rathmell
    • 2
  • Brian I. Rini
    • 3
  1. 1.David Geffen School of Medicine at UCLA, Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Lineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel HillUSA
  3. 3.Taussig Cancer Institute, Department of Solid Tumor OncologyCleveland ClinicCLEVELANDUSA

Bibliographic information

  • Book Title Renal Cell Carcinoma
  • Book Subtitle Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
  • Editors Robert A. Figlin
    W. Kimryn Rathmell
    Brian I. Rini
  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Springer, Boston, MA
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-1-4614-2399-7
  • Softcover ISBN 978-1-4899-9139-3
  • eBook ISBN 978-1-4614-2400-0
  • Edition Number 1
  • Number of Pages XII, 328
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods


From the reviews:

“The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. … certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC.” (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013)

“Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. … We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase.” (European Urology Today, June-July, 2012)

“This book by Figlin et al. is … timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. … We found it comprehensive, well written and well illustrated. … Overall, we found this to be an excellent book that we highly recommend. … It would be equally well placed on the shelf of physicians and researchers … and those with an interest in the field would do well to have read it.” (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)